HDAC9 and cancer: We noted that the inhibitory effect of sorafenib on HDAC activity in PLC5 cells was slightly attenuated at 48 h (Figure 3D), which implied that the HDAC-inhibitory ability of sorafenib was partially affected by the primary sorafenib-resistant property of cancer cells.